カテゴリー： QYResearch, 世界, 医療/バイオ

世界の横隔膜麻痺治療市場インサイト及び予測（ベータ遮断薬、炭酸脱水酵素阻害薬、その他）

◆英語タイトル：Global Paralyzed Diaphragm Treatment Market Insights, Forecast to 2028
	◆商品コード：QY22JLX09268 ◆発行会社（リサーチ会社）：QYResearch ◆発行日：2022年7月（※2025年版があります。お問い合わせください。） ◆ページ数：128 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後3営業日） ◆調査対象地域：グローバル ◆産業分野：医療

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD4,900 ⇒換算￥735,000	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD7,350 ⇒換算￥1,102,500	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD9,800 ⇒換算￥1,470,000	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、横隔膜麻痺治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に横隔膜麻痺治療の世界市場のxxx％を占める「ベータ遮断薬」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
横隔膜麻痺治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの横隔膜麻痺治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

横隔膜麻痺治療のグローバル主要企業には、F. Hoffmann-La Roche、Novartis AG、Pfizer、AbbVie、AstraZeneca、Baxter、Eli Lilly and Company、Johnson & Johnson Services、Merck KGaA、Novo Nordisk A/S、Bristol-Myers Squibb Company、Alexion Pharmaceuticals、Kyowa Hakko Kirin、Amgen、Biogen、Celldex Therapeutics、GlaxoSmithKline、Eisai、Takeda Pharmaceutical、Vertex Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

横隔膜麻痺治療市場は、種類と用途によって区分されます。世界の横隔膜麻痺治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ベータ遮断薬、炭酸脱水酵素阻害薬、その他

【用途別セグメント】
病院、在宅医療、専門クリニック、その他

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 横隔膜麻痺治療製品概要
- 種類別市場（ベータ遮断薬、炭酸脱水酵素阻害薬、その他）
- 用途別市場（病院、在宅医療、専門クリニック、その他）
- 調査の目的
・エグゼクティブサマリー
- 世界の横隔膜麻痺治療販売量予測2017-2028
- 世界の横隔膜麻痺治療売上予測2017-2028
- 横隔膜麻痺治療の地域別販売量
- 横隔膜麻痺治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別横隔膜麻痺治療販売量
- 主要メーカー別横隔膜麻痺治療売上
- 主要メーカー別横隔膜麻痺治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（ベータ遮断薬、炭酸脱水酵素阻害薬、その他）
- 横隔膜麻痺治療の種類別販売量
- 横隔膜麻痺治療の種類別売上
- 横隔膜麻痺治療の種類別価格
・用途別市場規模（病院、在宅医療、専門クリニック、その他）
- 横隔膜麻痺治療の用途別販売量
- 横隔膜麻痺治療の用途別売上
- 横隔膜麻痺治療の用途別価格
・北米市場
- 北米の横隔膜麻痺治療市場規模（種類別、用途別）
- 主要国別の横隔膜麻痺治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの横隔膜麻痺治療市場規模（種類別、用途別）
- 主要国別の横隔膜麻痺治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の横隔膜麻痺治療市場規模（種類別、用途別）
- 主要国別の横隔膜麻痺治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の横隔膜麻痺治療市場規模（種類別、用途別）
- 主要国別の横隔膜麻痺治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの横隔膜麻痺治療市場規模（種類別、用途別）
- 主要国別の横隔膜麻痺治療市場規模（トルコ、サウジアラビア）
・企業情報
F. Hoffmann-La Roche、Novartis AG、Pfizer、AbbVie、AstraZeneca、Baxter、Eli Lilly and Company、Johnson & Johnson Services、Merck KGaA、Novo Nordisk A/S、Bristol-Myers Squibb Company、Alexion Pharmaceuticals、Kyowa Hakko Kirin、Amgen、Biogen、Celldex Therapeutics、GlaxoSmithKline、Eisai、Takeda Pharmaceutical、Vertex Pharmaceuticals
・産業チェーン及び販売チャネル分析
- 横隔膜麻痺治療の産業チェーン分析
- 横隔膜麻痺治療の原材料
- 横隔膜麻痺治療の生産プロセス
- 横隔膜麻痺治療の販売及びマーケティング
- 横隔膜麻痺治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 横隔膜麻痺治療の産業動向
- 横隔膜麻痺治療のマーケットドライバー
- 横隔膜麻痺治療の課題
- 横隔膜麻痺治療の阻害要因
・主な調査結果

Diaphragm paralysis refers to the condition that includes loss of control of one or both sides of the diaphragm. This condition causes a reduction in lung capacity. Shortness of breath, blue lips and fingers, insomnia, headaches, fatigue, and overall breathing difficulty are some of the symptoms seen in the patients suffering from paralyzed diaphragm.
Market Analysis and Insights: Global Paralyzed Diaphragm Treatment Market
The global Paralyzed Diaphragm Treatment market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Beta-Blockers accounting for % of the Paralyzed Diaphragm Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Paralyzed Diaphragm Treatment market size is valued at US$ million in 2021, while the North America and Europe Paralyzed Diaphragm Treatment are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Paralyzed Diaphragm Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Paralyzed Diaphragm Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Paralyzed Diaphragm Treatment market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Paralyzed Diaphragm Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Paralyzed Diaphragm Treatment market.
Global Paralyzed Diaphragm Treatment Scope and Market Size
Paralyzed Diaphragm Treatment market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Paralyzed Diaphragm Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Beta-Blockers
Carbonic Anhydrase Inhibitor
Others
Segment by Application
Hospitals
Homecare
Specialty Clinics
Others
By Company
F. Hoffmann-La Roche
Novartis AG
Pfizer
AbbVie
AstraZeneca
Baxter
Eli Lilly and Company
Johnson & Johnson Services
Merck KGaA
Novo Nordisk A/S
Bristol-Myers Squibb Company
Alexion Pharmaceuticals
Kyowa Hakko Kirin
Amgen
Biogen
Celldex Therapeutics
GlaxoSmithKline
Eisai
Takeda Pharmaceutical
Vertex Pharmaceuticals
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Paralyzed Diaphragm Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Beta-Blockers
1.2.3 Carbonic Anhydrase Inhibitor
1.2.4 Others
1.3 Market by Application
1.3.1 Global Paralyzed Diaphragm Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Homecare
1.3.4 Specialty Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Paralyzed Diaphragm Treatment Market Perspective (2017-2028)
2.2 Paralyzed Diaphragm Treatment Growth Trends by Region
2.2.1 Paralyzed Diaphragm Treatment Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Paralyzed Diaphragm Treatment Historic Market Size by Region (2017-2022)
2.2.3 Paralyzed Diaphragm Treatment Forecasted Market Size by Region (2023-2028)
2.3 Paralyzed Diaphragm Treatment Market Dynamics
2.3.1 Paralyzed Diaphragm Treatment Industry Trends
2.3.2 Paralyzed Diaphragm Treatment Market Drivers
2.3.3 Paralyzed Diaphragm Treatment Market Challenges
2.3.4 Paralyzed Diaphragm Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Paralyzed Diaphragm Treatment Players by Revenue
3.1.1 Global Top Paralyzed Diaphragm Treatment Players by Revenue (2017-2022)
3.1.2 Global Paralyzed Diaphragm Treatment Revenue Market Share by Players (2017-2022)
3.2 Global Paralyzed Diaphragm Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Paralyzed Diaphragm Treatment Revenue
3.4 Global Paralyzed Diaphragm Treatment Market Concentration Ratio
3.4.1 Global Paralyzed Diaphragm Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Paralyzed Diaphragm Treatment Revenue in 2021
3.5 Paralyzed Diaphragm Treatment Key Players Head office and Area Served
3.6 Key Players Paralyzed Diaphragm Treatment Product Solution and Service
3.7 Date of Enter into Paralyzed Diaphragm Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Paralyzed Diaphragm Treatment Breakdown Data by Type
4.1 Global Paralyzed Diaphragm Treatment Historic Market Size by Type (2017-2022)
4.2 Global Paralyzed Diaphragm Treatment Forecasted Market Size by Type (2023-2028)
5 Paralyzed Diaphragm Treatment Breakdown Data by Application
5.1 Global Paralyzed Diaphragm Treatment Historic Market Size by Application (2017-2022)
5.2 Global Paralyzed Diaphragm Treatment Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Paralyzed Diaphragm Treatment Market Size (2017-2028)
6.2 North America Paralyzed Diaphragm Treatment Market Size by Type
6.2.1 North America Paralyzed Diaphragm Treatment Market Size by Type (2017-2022)
6.2.2 North America Paralyzed Diaphragm Treatment Market Size by Type (2023-2028)
6.2.3 North America Paralyzed Diaphragm Treatment Market Share by Type (2017-2028)
6.3 North America Paralyzed Diaphragm Treatment Market Size by Application
6.3.1 North America Paralyzed Diaphragm Treatment Market Size by Application (2017-2022)
6.3.2 North America Paralyzed Diaphragm Treatment Market Size by Application (2023-2028)
6.3.3 North America Paralyzed Diaphragm Treatment Market Share by Application (2017-2028)
6.4 North America Paralyzed Diaphragm Treatment Market Size by Country
6.4.1 North America Paralyzed Diaphragm Treatment Market Size by Country (2017-2022)
6.4.2 North America Paralyzed Diaphragm Treatment Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Paralyzed Diaphragm Treatment Market Size (2017-2028)
7.2 Europe Paralyzed Diaphragm Treatment Market Size by Type
7.2.1 Europe Paralyzed Diaphragm Treatment Market Size by Type (2017-2022)
7.2.2 Europe Paralyzed Diaphragm Treatment Market Size by Type (2023-2028)
7.2.3 Europe Paralyzed Diaphragm Treatment Market Share by Type (2017-2028)
7.3 Europe Paralyzed Diaphragm Treatment Market Size by Application
7.3.1 Europe Paralyzed Diaphragm Treatment Market Size by Application (2017-2022)
7.3.2 Europe Paralyzed Diaphragm Treatment Market Size by Application (2023-2028)
7.3.3 Europe Paralyzed Diaphragm Treatment Market Share by Application (2017-2028)
7.4 Europe Paralyzed Diaphragm Treatment Market Size by Country
7.4.1 Europe Paralyzed Diaphragm Treatment Market Size by Country (2017-2022)
7.4.2 Europe Paralyzed Diaphragm Treatment Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Paralyzed Diaphragm Treatment Market Size (2017-2028)
8.2 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Type
8.2.1 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Paralyzed Diaphragm Treatment Market Share by Type (2017-2028)
8.3 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Application
8.3.1 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Paralyzed Diaphragm Treatment Market Share by Application (2017-2028)
8.4 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Region
8.4.1 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Paralyzed Diaphragm Treatment Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Paralyzed Diaphragm Treatment Market Size (2017-2028)
9.2 Latin America Paralyzed Diaphragm Treatment Market Size by Type
9.2.1 Latin America Paralyzed Diaphragm Treatment Market Size by Type (2017-2022)
9.2.2 Latin America Paralyzed Diaphragm Treatment Market Size by Type (2023-2028)
9.2.3 Latin America Paralyzed Diaphragm Treatment Market Share by Type (2017-2028)
9.3 Latin America Paralyzed Diaphragm Treatment Market Size by Application
9.3.1 Latin America Paralyzed Diaphragm Treatment Market Size by Application (2017-2022)
9.3.2 Latin America Paralyzed Diaphragm Treatment Market Size by Application (2023-2028)
9.3.3 Latin America Paralyzed Diaphragm Treatment Market Share by Application (2017-2028)
9.4 Latin America Paralyzed Diaphragm Treatment Market Size by Country
9.4.1 Latin America Paralyzed Diaphragm Treatment Market Size by Country (2017-2022)
9.4.2 Latin America Paralyzed Diaphragm Treatment Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Paralyzed Diaphragm Treatment Market Size (2017-2028)
10.2 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Type
10.2.1 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Paralyzed Diaphragm Treatment Market Share by Type (2017-2028)
10.3 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Application
10.3.1 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Paralyzed Diaphragm Treatment Market Share by Application (2017-2028)
10.4 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Country
10.4.1 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Paralyzed Diaphragm Treatment Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 F. Hoffmann-La Roche
11.1.1 F. Hoffmann-La Roche Company Details
11.1.2 F. Hoffmann-La Roche Business Overview
11.1.3 F. Hoffmann-La Roche Paralyzed Diaphragm Treatment Introduction
11.1.4 F. Hoffmann-La Roche Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.1.5 F. Hoffmann-La Roche Recent Developments
11.2 Novartis AG
11.2.1 Novartis AG Company Details
11.2.2 Novartis AG Business Overview
11.2.3 Novartis AG Paralyzed Diaphragm Treatment Introduction
11.2.4 Novartis AG Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.2.5 Novartis AG Recent Developments
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Paralyzed Diaphragm Treatment Introduction
11.3.4 Pfizer Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.3.5 Pfizer Recent Developments
11.4 AbbVie
11.4.1 AbbVie Company Details
11.4.2 AbbVie Business Overview
11.4.3 AbbVie Paralyzed Diaphragm Treatment Introduction
11.4.4 AbbVie Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.4.5 AbbVie Recent Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Details
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Paralyzed Diaphragm Treatment Introduction
11.5.4 AstraZeneca Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.5.5 AstraZeneca Recent Developments
11.6 Baxter
11.6.1 Baxter Company Details
11.6.2 Baxter Business Overview
11.6.3 Baxter Paralyzed Diaphragm Treatment Introduction
11.6.4 Baxter Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.6.5 Baxter Recent Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Details
11.7.2 Eli Lilly and Company Business Overview
11.7.3 Eli Lilly and Company Paralyzed Diaphragm Treatment Introduction
11.7.4 Eli Lilly and Company Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.7.5 Eli Lilly and Company Recent Developments
11.8 Johnson & Johnson Services
11.8.1 Johnson & Johnson Services Company Details
11.8.2 Johnson & Johnson Services Business Overview
11.8.3 Johnson & Johnson Services Paralyzed Diaphragm Treatment Introduction
11.8.4 Johnson & Johnson Services Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.8.5 Johnson & Johnson Services Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Paralyzed Diaphragm Treatment Introduction
11.9.4 Merck KGaA Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.9.5 Merck KGaA Recent Developments
11.10 Novo Nordisk A/S
11.10.1 Novo Nordisk A/S Company Details
11.10.2 Novo Nordisk A/S Business Overview
11.10.3 Novo Nordisk A/S Paralyzed Diaphragm Treatment Introduction
11.10.4 Novo Nordisk A/S Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.10.5 Novo Nordisk A/S Recent Developments
11.11 Bristol-Myers Squibb Company
11.11.1 Bristol-Myers Squibb Company Company Details
11.11.2 Bristol-Myers Squibb Company Business Overview
11.11.3 Bristol-Myers Squibb Company Paralyzed Diaphragm Treatment Introduction
11.11.4 Bristol-Myers Squibb Company Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.11.5 Bristol-Myers Squibb Company Recent Developments
11.12 Alexion Pharmaceuticals
11.12.1 Alexion Pharmaceuticals Company Details
11.12.2 Alexion Pharmaceuticals Business Overview
11.12.3 Alexion Pharmaceuticals Paralyzed Diaphragm Treatment Introduction
11.12.4 Alexion Pharmaceuticals Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.12.5 Alexion Pharmaceuticals Recent Developments
11.13 Kyowa Hakko Kirin
11.13.1 Kyowa Hakko Kirin Company Details
11.13.2 Kyowa Hakko Kirin Business Overview
11.13.3 Kyowa Hakko Kirin Paralyzed Diaphragm Treatment Introduction
11.13.4 Kyowa Hakko Kirin Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.13.5 Kyowa Hakko Kirin Recent Developments
11.14 Amgen
11.14.1 Amgen Company Details
11.14.2 Amgen Business Overview
11.14.3 Amgen Paralyzed Diaphragm Treatment Introduction
11.14.4 Amgen Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.14.5 Amgen Recent Developments
11.15 Biogen
11.15.1 Biogen Company Details
11.15.2 Biogen Business Overview
11.15.3 Biogen Paralyzed Diaphragm Treatment Introduction
11.15.4 Biogen Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.15.5 Biogen Recent Developments
11.16 Celldex Therapeutics
11.16.1 Celldex Therapeutics Company Details
11.16.2 Celldex Therapeutics Business Overview
11.16.3 Celldex Therapeutics Paralyzed Diaphragm Treatment Introduction
11.16.4 Celldex Therapeutics Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.16.5 Celldex Therapeutics Recent Developments
11.17 GlaxoSmithKline
11.17.1 GlaxoSmithKline Company Details
11.17.2 GlaxoSmithKline Business Overview
11.17.3 GlaxoSmithKline Paralyzed Diaphragm Treatment Introduction
11.17.4 GlaxoSmithKline Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.17.5 GlaxoSmithKline Recent Developments
11.18 Eisai
11.18.1 Eisai Company Details
11.18.2 Eisai Business Overview
11.18.3 Eisai Paralyzed Diaphragm Treatment Introduction
11.18.4 Eisai Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.18.5 Eisai Recent Developments
11.19 Takeda Pharmaceutical
11.19.1 Takeda Pharmaceutical Company Details
11.19.2 Takeda Pharmaceutical Business Overview
11.19.3 Takeda Pharmaceutical Paralyzed Diaphragm Treatment Introduction
11.19.4 Takeda Pharmaceutical Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.19.5 Takeda Pharmaceutical Recent Developments
11.20 Vertex Pharmaceuticals
11.20.1 Vertex Pharmaceuticals Company Details
11.20.2 Vertex Pharmaceuticals Business Overview
11.20.3 Vertex Pharmaceuticals Paralyzed Diaphragm Treatment Introduction
11.20.4 Vertex Pharmaceuticals Revenue in Paralyzed Diaphragm Treatment Business (2017-2022)
11.20.5 Vertex Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の横隔膜麻痺治療市場インサイト及び予測（ベータ遮断薬、炭酸脱水酵素阻害薬、その他）(Global Paralyzed Diaphragm Treatment Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の横隔膜麻痺治療市場インサイト及び予測（ベータ遮断薬、炭酸脱水酵素阻害薬、その他）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp